Riluzole is a glutamate antagonist used to treat amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
- Mechanism
- Curator reviewed
The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
- Primary indication
- For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)Curator reviewed · 1 structured indication
- Formula / weight
- C8H5F3N2OS · 234.198 g/mol (avg)
- First approval
- Canada, 2006 · United States, 1995 · European Union, 2016
- Code names
- BF-37 · BHV-0223 · PK 26124 · RP 54274 · RPR 202
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
FTALBRSUTCGOEG-UHFFFAOYSA-NSMILESNC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2Transporters
What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Riluzole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account